Cargando…

Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis

BACKGROUND: Determining the relative cost-effectiveness between advanced therapeutic options for ulcerative colitis (UC) may optimize resource utilization. We evaluated total cost per response, cost per remission, and cost of safety events for patients with moderately-to-severely active UC after 52 ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jairath, Vipul, Cohen, Russell D., Loftus, Edward V., Candela, Ninfa, Lasch, Karen, Schultz, Bob G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724317/ https://www.ncbi.nlm.nih.gov/pubmed/36474165 http://dx.doi.org/10.1186/s12876-022-02590-6

Ejemplares similares

Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies
por: Sandborn, William J, et al.
Publicado: (2023)

Reliability of the Endoscopic Ultrasound Ulcerative Colitis (EUS-UC) score for assessment of inflammation in patients with ulcerative colitis
por: Yan, Brian M., et al.
Publicado: (2021)

Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis
por: Schultz, Bob G, et al.
Publicado: (2021)

Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine
por: Oliveira, Lilliana, et al.
Publicado: (2011)

Ozanimod Therapy in a Patient With Ulcerative Colitis and Multiple Sclerosis: Hitting 2 Birds With 1 Stone
por: Vuyyuru, Sudheer K., et al.
Publicado: (2023)

Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures
por: Neumann, Peter J., et al.
Publicado: (2018)

Therapeutic Potential of Proanthocyanidins in Ulcerative Colitis in Remission
por: Głąbska, Dominika, et al.
Publicado: (2020)

Transcriptional Signatures That Define Ulcerative Colitis in Remission
por: Fenton, Christopher G, et al.
Publicado: (2020)

Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis
por: Sandborn, William J, et al.
Publicado: (2019)

Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review
por: Caron, Bénédicte, et al.
Publicado: (2022)

Healthcare costs and mortality associated with serious fluoroquinolone‐related adverse reactions
por: Kuula, Laura S.M., et al.
Publicado: (2022)

Remission of ulcerative colitis flare-up induced by nivolumab
por: Iwamoto, Maho, et al.
Publicado: (2020)

Dose Escalation of Biologics in Biologic-Naïve Patients With Ulcerative Colitis: Outcomes From the ODESSA-UC Study
por: Ghosh, Sabyasachi, et al.
Publicado: (2023)

Costs associated with adverse events from remission induction for children with Acute Lymphoblastic Leukemia (ALL)
por: Mejía-Aranguré, Eréndira, et al.
Publicado: (2022)

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
por: Xie, Feng, et al.
Publicado: (2009)

A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis
por: Stawowczyk, Ewa, et al.
Publicado: (2017)

Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis
por: Dulai, Parambir S., et al.
Publicado: (2020)

Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis
por: Lu, Xiaoyan, et al.
Publicado: (2022)

Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis
por: Mitra, Debanjali, et al.
Publicado: (2012)

The Comparative Risk of Serious Adverse Events With Tofacitinib and TNF Inhibitors in Patients With Ulcerative Colitis: The Korean Experience as Revealed by a National Database
por: Seo, Gi Hyeon, et al.
Publicado: (2022)

Correction to: Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis
por: Lu, Xiaoyan, et al.
Publicado: (2023)

Healing of the epithelial barrier in the ileum is superior to endoscopic and histologic remission for predicting major adverse outcomes in ulcerative colitis
por: Rath, Timo, et al.
Publicado: (2023)

Correlation of Biomarkers with Endoscopic Score: Ulcerative Colitis Endoscopic Index of Severity (UCEIS) in Patients with Ulcerative Colitis in Remission
por: Pop, Corina Silvia, et al.
Publicado: (2020)

Rapid Induction and Maintenance of Remission in Refractory Ulcerative Colitis with Ustekinumab
por: Chen, An-Yu, et al.
Publicado: (2019)

Real-life evaluation of histologic scores for Ulcerative Colitis in remission
por: Arkteg, Christian Børde, et al.
Publicado: (2021)

Analysis of Endoscopic Evaluation Reliability for Ulcerative Colitis in Histological Remission
por: Kanazawa, Mimari, et al.
Publicado: (2021)

The Cost of Nursing per Bed
Publicado: (1909)

Time spent per day in strenuous activity and total physical activity are inversely associated with mucosal healing but not with clinical remission in patients with ulcerative colitis
por: Watanabe, Junichi, et al.
Publicado: (2021)

Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis
por: Haga, Keiichi, et al.
Publicado: (2022)

Cost-Effectiveness of Infliximab for the Treatment of Acute Exacerbations of Ulcerative Colitis in the Netherlands
por: Chaudhary, Mohammad A., et al.
Publicado: (2012)

Disease activity, quality of life, and indirect costs of ulcerative colitis in Poland
por: Kawalec, Paweł, et al.
Publicado: (2017)

Cost-effectiveness of biological treatment of ulcerative colitis – a systematic review
por: Stawowczyk, Ewa, et al.
Publicado: (2017)

Telemonitoring of Crohn’s Disease and Ulcerative Colitis (TECCU): Cost-Effectiveness Analysis
por: Del Hoyo, Javier, et al.
Publicado: (2019)

Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada
por: Fenu, Elisabetta, et al.
Publicado: (2022)

Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes
por: Magro, Fernando, et al.
Publicado: (2023)

A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted
por: Neumann, Peter J., et al.
Publicado: (2016)

Association of endoscopic and histological remission with clinical course in patients of ulcerative colitis
por: Narang, Vikram, et al.
Publicado: (2018)

Efficacy of Bifidobacterium breve Fermented Milk in Maintaining Remission of Ulcerative Colitis
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2018)

Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis
por: Paschos, Paschalis, et al.
Publicado: (2018)

Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis
por: Feagan, Brian G, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3em9qfjuecdc0on2lij2mc2mrm